Key regions: France, India, United Kingdom, South Korea, Japan
The demand for Multiple Sclerosis Drugs in Qatar has been steadily increasing in recent years.
Customer preferences: Patients suffering from Multiple Sclerosis in Qatar are increasingly seeking out new and innovative treatments to manage their symptoms. This has led to a growing demand for drugs that are effective in reducing the frequency and severity of relapses, as well as those that can help slow the progression of the disease. Patients are also looking for drugs that are easy to administer and have minimal side effects.
Trends in the market: The Multiple Sclerosis Drugs market in Qatar is expected to grow at a steady pace over the next few years. The market is being driven by a number of factors, including an increasing prevalence of the disease, a growing awareness of the condition, and the availability of new and innovative drugs. In addition, the government of Qatar has been investing heavily in healthcare infrastructure, which has helped to increase access to treatment for patients with Multiple Sclerosis.
Local special circumstances: One of the unique challenges facing the Multiple Sclerosis Drugs market in Qatar is the relatively small size of the market. This has made it difficult for drug manufacturers to justify investing in research and development for drugs specifically targeted at the Qatari market. As a result, many of the drugs available in Qatar are imported from other countries.
Underlying macroeconomic factors: The Qatari economy has been growing steadily in recent years, which has helped to increase access to healthcare for the population. In addition, the government has been investing heavily in healthcare infrastructure, which has helped to improve the quality of care available to patients with Multiple Sclerosis. However, the ongoing blockade of Qatar by several other countries in the region has had a negative impact on the economy, which could potentially slow the growth of the Multiple Sclerosis Drugs market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
